LLY: Eli Lilly & Co. Company Profile & Statistics

About

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Info & Links

CEO

David Ricks

Headquarters

LILLY CORPORATE CENTER
INDIANAPOLIS, IN 46285, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

17,903

Employees

47,000

Eli Lilly & Co. Statistics

Valuation Measures

Market Capitalization²

824.39B

Enterprise Value

854.77B

Enterprise Value/EBITDA(ttm)

58.28

Price to Earnings Ratio(ttm)

67.16

Price to Sales(ttm)

18.38

Price to Book(mrq)

58.08

Price to Cash(ytd)

61.34

Profitability

Gross Margin(ttm)

81.24%

Operating Margin(ttm)

26.08%

Profit Margin(ttm)

23.22%

Return on Equity(ttm)

85.24%

Return on Invested Capital(ttm)

26.47%

Return on Assets(ttm)

16.19%

Income Statement

Revenue(ttm)

45.04B

Revenue Per Share(ttm)

47.50

Gross Profit(ttm)

36.62B

EBITDA(ttm)³

14.67B

Net Income Available to Common(ttm)

10.59B

Diluted EPS(ttm)

11.71

Share Statistics

Beta (5Y Monthly)

0.42

52-Week Change

21.96%

S&P 500 52-Week Change

10.97%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

948.17M

Dividend Yield

0.69%

Float⁴

948.08M

% Held by Insiders

0.13%

% Held by Institutions

82.53%

Balance Sheet

Total Cash(mrq)

3.42B

Total Cash Per Share(mrq)

3.61

Total Debt(mrq)

33.64B

Total Debt/Equity(mrq)

235.74%

Current Ratio(mrq)

1.15%

Quick Ratio(mrq)

0.97%

Book Value Per Share(mrq)

15.06

Cash Flow

Operating Cash Flow Per Share(ytd)

9.75

Free Cash Flow(ytd)

3.76B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

LLY

Eli Lilly & Co.

Eli Lilly & Co. Profile